Advice
Following a full submission
carglumic acid (Carbaglu) is accepted for restricted use within NHS Scotland for the treatment of hyperammonaemia due to N-acetylglutamate synthase deficiency. Limited data from retrospective case analysis indicate that carglumic acid generally allowed patients to maintain normal ammonia levels, growth and psychomotor development.
Carglumic acid is restricted to use by experts providing the supraregional specialist service for this disease.
Download detailed advice42KB (PDF)
Medicine details
- Medicine name:
- carglumic acid 200mg dispersible tablets (Carbaglu)
- SMC ID:
- 299/06
- Indication:
- Hyperammonaemia due to N-acetylglutamate synthase deficiency
- Pharmaceutical company
- Orphan Europe (UK) Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 09 October 2006